Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 166

Similar articles for PubMed (Select 18056197)

1.
2.

Tumor-directed radiation and the immunotoxin SS1P in the treatment of mesothelin-expressing tumor xenografts.

Hassan R, Williams-Gould J, Steinberg SM, Liewehr DJ, Yokokawa J, Tsang KY, Surawski RJ, Scott T, Camphausen K.

Clin Cancer Res. 2006 Aug 15;12(16):4983-8.

3.

Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice.

Zhang Y, Xiang L, Hassan R, Paik CH, Carrasquillo JA, Jang BS, Le N, Ho M, Pastan I.

Clin Cancer Res. 2006 Aug 1;12(15):4695-701.

4.

Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice.

Filpula D, Yang K, Basu A, Hassan R, Xiang L, Zhang Z, Wang M, Wang QC, Ho M, Beers R, Zhao H, Peng P, Zhou J, Li X, Petti G, Janjua A, Liu J, Wu D, Yu D, Zhang Z, Longley C, FitzGerald D, Kreitman RJ, Pastan I.

Bioconjug Chem. 2007 May-Jun;18(3):773-84. Epub 2007 Mar 9.

PMID:
17346030
5.

Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors.

Zhang Y, Xiang L, Hassan R, Pastan I.

Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):17099-104. Epub 2007 Oct 16.

6.

Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine.

Kimura K, Sawada T, Komatsu M, Inoue M, Muguruma K, Nishihara T, Yamashita Y, Yamada N, Ohira M, Hirakawa K.

Clin Cancer Res. 2006 Aug 15;12(16):4925-32.

7.

Enhanced antitumor efficacy by the combination of emodin and gemcitabine against human pancreatic cancer cells via downregulation of the expression of XIAP in vitro and in vivo.

Wang ZH, Chen H, Guo HC, Tong HF, Liu JX, Wei WT, Tan W, Ni ZL, Liu HB, Lin SZ.

Int J Oncol. 2011 Nov;39(5):1123-31. doi: 10.3892/ijo.2011.1115. Epub 2011 Jul 6.

PMID:
21743963
8.

Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.

Bianco C, Giovannetti E, Ciardiello F, Mey V, Nannizzi S, Tortora G, Troiani T, Pasqualetti F, Eckhardt G, de Liguoro M, Ricciardi S, Del Tacca M, Raben D, Cionini L, Danesi R.

Clin Cancer Res. 2006 Dec 1;12(23):7099-107.

9.

Killing of resistant cancer cells with low Bak by a combination of an antimesothelin immunotoxin and a TRAIL Receptor 2 agonist antibody.

Du X, Xiang L, Mackall C, Pastan I.

Clin Cancer Res. 2011 Sep 15;17(18):5926-34. doi: 10.1158/1078-0432.CCR-11-1235. Epub 2011 Aug 3.

10.

Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo.

O'Reilly T, McSheehy PM, Wartmann M, Lassota P, Brandt R, Lane HA.

Anticancer Drugs. 2011 Jan;22(1):58-78. doi: 10.1097/CAD.0b013e3283400a20.

PMID:
20890178
11.

Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro.

Hassan R, Lerner MR, Benbrook D, Lightfoot SA, Brackett DJ, Wang QC, Pastan I.

Clin Cancer Res. 2002 Nov;8(11):3520-6.

12.

Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human HT-29 colon carcinoma and human CaKi1 renal cell carcinoma xenografts.

Teicher BA, Menon K, Alvarez E, Galbreath E, Shih C, Faul MM.

Anticancer Res. 2001 Sep-Oct;21(5):3175-84.

PMID:
11848470
13.

Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer.

Banerjee S, Zhang Y, Ali S, Bhuiyan M, Wang Z, Chiao PJ, Philip PA, Abbruzzese J, Sarkar FH.

Cancer Res. 2005 Oct 1;65(19):9064-72.

14.

Antitumor effects of immunotoxins are enhanced by lowering HCK or treatment with SRC kinase inhibitors.

Liu XF, Xiang L, FitzGerald DJ, Pastan I.

Mol Cancer Ther. 2014 Jan;13(1):82-9. doi: 10.1158/1535-7163.MCT-13-0726. Epub 2013 Oct 21.

15.

Anti-tumor activity of K1-LysPE38QQR, an immunotoxin targeting mesothelin, a cell-surface antigen overexpressed in ovarian cancer and malignant mesothelioma.

Hassan R, Viner JL, Wang QC, Margulies I, Kreitman RJ, Pastan I.

J Immunother. 2000 Jul-Aug;23(4):473-9.

PMID:
10916757
16.

HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity.

Bang S, Nagata S, Onda M, Kreitman RJ, Pastan I.

Clin Cancer Res. 2005 Feb 15;11(4):1545-50.

17.

Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.

Bruns CJ, Harbison MT, Davis DW, Portera CA, Tsan R, McConkey DJ, Evans DB, Abbruzzese JL, Hicklin DJ, Radinsky R.

Clin Cancer Res. 2000 May;6(5):1936-48.

18.

Emodin potentiates the antitumor effects of gemcitabine in PANC-1 pancreatic cancer xenograft model in vivo via inhibition of inhibitors of apoptosis.

Guo HC, Bu HQ, Luo J, Wei WT, Liu DL, Chen H, Tong HF, Wang ZH, Wu HY, Li HH, Zuo MM, Li W, Lin SZ.

Int J Oncol. 2012 Jun;40(6):1849-57. doi: 10.3892/ijo.2012.1389. Epub 2012 Feb 29.

PMID:
22378302
19.

Synergistic activity of troxacitabine (Troxatyl) and gemcitabine in pancreatic cancer.

Damaraju VL, Bouffard DY, Wong CK, Clarke ML, Mackey JR, Leblond L, Cass CE, Grey M, Gourdeau H.

BMC Cancer. 2007 Jul 3;7:121.

20.

Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin.

Hassan R, Ebel W, Routhier EL, Patel R, Kline JB, Zhang J, Chao Q, Jacob S, Turchin H, Gibbs L, Phillips MD, Mudali S, Iacobuzio-Donahue C, Jaffee EM, Moreno M, Pastan I, Sass PM, Nicolaides NC, Grasso L.

Cancer Immun. 2007 Dec 19;7:20.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk